These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Chitasombat MN; Kontoyiannis DP Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603 [TBL] [Abstract][Full Text] [Related]
11. Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. Marty FM; Cornely OA; Mullane KM; Ostrosky-Zeichner L; Maher RM; Croos-Dabrera R; Lu Q; Lademacher C; Oren I; Schmitt-Hoffmann AH; Giladi M; Rahav G; Perfect JR Mycoses; 2018 Jul; 61(7):485-497. PubMed ID: 29611227 [TBL] [Abstract][Full Text] [Related]
12. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds. Pfaller MA; Rhomberg PR; Castanheira M Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424 [TBL] [Abstract][Full Text] [Related]
13. Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. Samanta P; Clancy CJ; Marini RV; Rivosecchi RM; McCreary EK; Shields RK; Falcione BA; Viehman A; Sacha L; Kwak EJ; Silveira FP; Sanchez PG; Morrell M; Clarke L; Nguyen MH Clin Infect Dis; 2021 Aug; 73(3):416-426. PubMed ID: 32463873 [TBL] [Abstract][Full Text] [Related]
14. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Marty FM; Ostrosky-Zeichner L; Cornely OA; Mullane KM; Perfect JR; Thompson GR; Alangaden GJ; Brown JM; Fredricks DN; Heinz WJ; Herbrecht R; Klimko N; Klyasova G; Maertens JA; Melinkeri SR; Oren I; Pappas PG; Ráčil Z; Rahav G; Santos R; Schwartz S; Vehreschild JJ; Young JH; Chetchotisakd P; Jaruratanasirikul S; Kanj SS; Engelhardt M; Kaufhold A; Ito M; Lee M; Sasse C; Maher RM; Zeiher B; Vehreschild MJGT; Lancet Infect Dis; 2016 Jul; 16(7):828-837. PubMed ID: 26969258 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. Bogler Y; Stern A; Su Y; Lee YJ; Seo SK; Shaffer B; Perales MA; Papanicolaou GA; Neofytos D Med Mycol; 2021 Oct; 59(10):970-979. PubMed ID: 34036319 [TBL] [Abstract][Full Text] [Related]
16. Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. Rivosecchi RM; Clancy CJ; Shields RK; Ensor CR; Shullo MA; Falcione BA; Venkataramanan R; Nguyen MH Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674051 [TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327 [TBL] [Abstract][Full Text] [Related]
18. Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trial. Horn D; Goff D; Khandelwal N; Spalding J; Azie N; Shi F; Franks B; Shorr AF J Med Econ; 2016 Jul; 19(7):728-34. PubMed ID: 26960060 [TBL] [Abstract][Full Text] [Related]
19. Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials. Andes DR; Ghannoum MA; Mukherjee PK; Kovanda LL; Lu Q; Jones ME; Santerre Henriksen A; Lademacher C; Hope WW Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373791 [TBL] [Abstract][Full Text] [Related]
20. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Ananda-Rajah MR; Kontoyiannis D Future Microbiol; 2015; 10(5):693-708. PubMed ID: 26000646 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]